2. U.S. centers of academic biotechnology research have closer connections with private biotechnology companies than do their European counterparts. What effect might this have on the pace of creation and development of new drugs in the United States versus Europe?
It is likely that the United States will experience a greater pace of creation and development of new drugs because closer links between private companies and academic research centers will lead to work more directly focused on producing new drugs rather than on pure research.